Britain and America have hammered out a key trade agreement that will preserve no import taxes on British medicine shipments being sold in the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has agreed to raise expenditure on drugs through the NHS. This commitment guarantees that import taxes on these vital exports will be held at nothing for a timeframe of 36 months.
This agreement comes after recent statements to hike import taxes on patented pharmaceutical imports, with potential rates mentioned up to one hundred percent.
"This arrangement with the United Kingdom bolsters the global environment for innovative medicines and brings much-needed fairness to American-British medicine commerce," an announcement noted.
Trade Significance
Pharmaceuticals are one of the the United Kingdom's largest exports to the America, which is easily the biggest destination for leading UK drugmakers.
Export figures reveal that in the year prior to the third quarter, the UK shipped drugs worth £11.1bn to the US. This amount accounted for a significant portion of all goods exports in that period.
"This agreement protects work, stimulates investment and sets the stage for the UK to establish itself as a worldwide center for life sciences," a minister stated.
Detailed UK Commitments
The agreement entails several key changes from the UK:
- Price Threshold Increase: The UK will increase the affordability limit at which it considers new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to double total NHS spending on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The sum pharmaceutical firms must return to the NHS to prevent overspending will be restricted at 15%. Last year, refunds were more than 20%.
Industry Background
The deal comes amid a protracted row between the sector and the UK government over spending levels and regulatory access.
This friction were heightened by assertions that US patients were charged several times more for the same drugs than people in the other developed nations.
Over the last 18 months, several significant drug company projects in the UK have been delayed or abandoned, while multi-billion-dollar investments have been announced toward projects in the United States.
One official publicly accepted that the NHS must increase expenditure on treatments, noting that its spending on drugs had declined as a share of its resources over the previous ten-year period.
